Goldman Sachs reports Q1 2024 sales of $14.21 billion, up 16% Y/Y, surpassing expectations. Global Banking & Markets sales hit $9.73 billion, while Asset & Wealth Management reached $3.79B. EPS stands at $11.58, with a 28% profit increase to $4.13 billion.
Volatility surged as geopolitical tensions rose in the Middle East and inflation data defied estimates, delaying rate cuts and causing concern for stocks, mortgages and consumer sentiment.
BlackRock faces setback in UK tax appeal related to $13.5 billion Barclays Global Investors acquisition. Court of Appeal's decision concluded lengthy legal dispute over tax deductions.
Federal regulators, including SEC and OCC, probe Morgan Stanley's client vetting for money laundering. Treasury and Fed consider actions. Focus on client investigations and financial activity monitoring.
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority, dismissing Lilly's state law maneuvering.
Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safety record, emphasizing positive outcomes for millions of treated animals.
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough reviews and data analyses, no changes to product information were deemed necessary.